Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC
The overall survival results from the MARIPOSA study have, for the first time in the history of EGFR-mutated advanced NSCLC, demonstrated a statistically significant OS improvement for lazertinib in combination with amivantamab compared to standard monotherapy with Osimertinib.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
